Sales and Marketing

Showing 15 posts of 11528 posts found.

Sun Pharmaceuticals hit with recall of over 31 thousand bottles of anti-depressants

October 13, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, India, US, america, sun pharmaceutical

Sun Pharmaceuticals have been forced to recall 31,762 bottles of anti-depressants from the US market after the FDA issued a …

Novartis’ Zykadia more effective than chemo, new study shows

October 13, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alcensa, Novartis, Roche, Xalkori, ceritinib, crizotinib, lung cancer, zykadia

Phase III results for Novartis’ cancer drug Zykadia (ceritinib) have revealed it as more effective than chemo at halting progression …

Nestlé appoints Paul Navarre as CEO of Nestlé Skin Health

October 12, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Nestle skin health, Paul Navarre, nestle

The announcement of Paul Navarre’s appointed as CEO of Nestlé Skin Health was announced on 11 October. He will take …

NICE backs Celgene’s Otezla for psoriatic arthritis

October 12, 2016 Research and Development, Sales and Marketing Celgene, NICE, otezla

The national Institute of Health and Care Excellence has issued recommendation of Celgene’s Otezla (apremilast) for the treatment of psoriatic …

Sanofi appoint Alan Main to Executive Committee and Executive Vice President Consumer Healthcare

October 11, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Sanofi announced the appointment of Alan Main as Executive Vice President Consumer Healthcare effective October 1.Mr Main, who previously worked …

New UK & Ireland general manager for Teva

October 10, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva, appointment

Kim Innes has been appointed by Teva as its new general manager of UK & Ireland. Innes succeeds Richard Daniell, …

Educating pharma

October 10, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing educated, funding, medical education, transparency

Originally published in the October issue of Pharmafocus, Sean Murray takes a look at how pharma continues to occupy a key …

Failure for BMS’ Opdivo in lung cancer trial

October 10, 2016 Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq

Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …

Roche’s lung cancer success spells competition for BMS’ Opdivo

October 10, 2016 Research and Development, Sales and Marketing BMS, Roche, lung cancer, opdivo, tecentriq

Roche’s immune-system booster drug Tecentriq (atezolizumab) may cause trouble in the lung cancer field for leader Bristol-Myers Squibb’s Opdivo according …

MSD’s Keytruda twice as successful against standard therapy for lung cancer

October 10, 2016 Sales and Marketing Bristol-Myers Squibb, MSD, Merck, keytruda

MSD, known as Merck in North America, released data that displayed the success of their drug, Keytruda, in a 123-patient …

Mylan agrees $465m settlement over EpiPen misclassification

October 10, 2016 Business Services, Medical Communications, Sales and Marketing Heather Bresch, Mylan, Price hike, epipen

In the latest scandal in the EpiPen price hike saga, the US Department of Justice has made claims that the …

Novartis’ new drug muscles in on Pfizer’s territory

October 10, 2016 Sales and Marketing Eli Lilly, Novartis, Pfizer, ibrance, ribociclib

A drug developed by Novartis, ribociclib, when combined with an older drug, letrozole, has been shown to reduce risk of progression …

Teva to sell Allergan’s UK & Ireland generics business for $770m

October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva

Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.
The Gateway to Local Adoption Series

Latest content